SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients

Study Population

Dialysis Clinic, Incorporated (DCI) is the largest non-profit provider of kidney care and dialysis care in the United States, operating 260 outpatient dialysis clinics in 29 states, 20 chronic kidney disease clinics in 5 states, and 3 organ procurement organizations in 3 states. All adult (age ≥18 years) maintenance dialysis patients treated between February 1 and October 02, 2021 in DCI clinics contributed time-at-risk, excluding patients with known COVID-19 diagnosis prior to February 1, 2021, transient patients (e.g. visiting from a non-DCI clinic) and/or patients treated for acute kidney injury who were not certified as end-stage renal disease (ESRD).

Screening for COVID-19

All maintenance dialysis patients treated at DCI outpatient facilities, including home dialysis and in-center dialysis patients, are screened at each clinic encounter for COVID-19 symptoms and any known exposure to infected person(s). These symptoms include fever (≥100 degrees), sore throat, new or worsening cough or shortness of breath, and loss of taste or smell. The vast majority of maintenance dialysis patients (>85%) are treated by in-center dialysis and are screened before each treatment, most often thrice weekly, while home dialysis patients typically are screened once or twice each month during visits to the dialysis facility. Any patient who screens positive is classified as a “Patient Under Investigation” and is tested for SARS-CoV-2 either locally or through the DCI laboratory. Most dialysis patients have multiple comorbid illnesses and have frequent contact with the healthcare system where they are tested even when asymptomatic. Similarly, many patients who are residents of congregate home settings, such as nursing homes, are frequently screened and tested as well. The diagnosis of COVID-19 is entered into DCI’s electronic health record (EHR), often based on a report of a positive SARS-CoV-2 test result, which if performed via the DCI laboratory, utilizes a reverse transcriptase–polymerase chain reaction (RT-PCR) Cobas SARS-CoV-2 Assay [Roche Diagnostics].

SARS-CoV-2 Antibody Testing

The DCI central laboratory assesses serum anti-spike IgG antibody against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike antigen using a US-FDA-EUA-approved chemiluminescent assay (ADVIA Centaur® XP/XPT COV2G). This semi-quantitative assay has a range between 0 and ≥20. The manufacturer defined threshold for a minimum antibody detection level is ≥1.⁹ This test is available for physicians to order either one time or as part of a clinical testing protocol, but is not measured in all maintenance dialysis patients routinely, per present CDC guidelines.¹⁰ The clinical testing protocol follows monthly anti-spike IgG titers using residual blood from routine monthly lab draws until the level is <1 for two consecutive months or for up to 12 consecutive months.

Outcomes

New COVID-19 diagnoses were documented based on screening as described above, or from contacts with other healthcare settings, such as hospitals and emergency department visits or clinic visits. All new COVID-19 diagnoses that occurred during the study period were each assigned to the appropriate vaccination status. For all breakthrough cases, defined as a COVID-19 diagnosis in a patient deemed fully vaccinated, the clinic was contacted to verify the reason why the patient was tested for SARS-CoV-2: for exposure to a known COVID-19 infected person or for symptoms/signs consistent with COVID-19 or as required by a non-dialysis clinic/hospital protocol prior to providing a COVID-unrelated service/procedure (e.g. vascular access surgery) or as part of protocolized screening (e.g. nursing home). COVID-19 related hospitalizations or deaths were defined by documented primary diagnosis for the episode of care as COVID-19 (ICD-10 code U01.7).

COVID-19 cases, hospitalizations and deaths were identified throughout the study period, and further subdivided into pre-COVID-19 delta variant (February 1, 2021 - June 25, 2021) and COVID-19 delta variant dominant periods (June 26, 2021 - October 02, 2021). The end of the follow up period to identify any patient diagnosed with COVID-19 on October 2, 2021 or earlier as having a COVID-19 related hospitalization or death within 30 days of diagnosis was November 02, 2021.

Data Extraction and Analysis

All patient demographic and clinical variables used in this analyses were retrospectively obtained from the DCI EHR. These variables include: SARS-CoV-2 vaccine name and dates administered, age, sex, race (Black, White, Native American, Asian/Pacific Islander, Other/Unknown), ethnicity (Hispanic or Non-Hispanic), US state and county of residence, congregate living status (e.g., nursing home, long term care facility), modality (in-center hemodialysis, home hemodialysis, peritoneal dialysis), date of ESRD, body mass index, dialysis dose delivered (Kt/V), serum albumin, hepatitis B surface antibody, immunosuppression (immune-modulating medications, prior transplant, immunodeficiency disorder), substance abuse disorder (tobacco, alcohol or drug), and other comorbid conditions. For this study, any SARS-CoV-2 infection occurring more than 14 days after completing SARS-CoV-2 vaccination was deemed a breakthrough COVID-19 case even if asymptomatic. Data integrity checks for COVID-19 documentation are performed weekly. These include comparing consistency of all available concurrent documentation, including: de novo ICD-10 COVID-19 diagnoses within the problem list, Patient Under Investigation status during symptom screening every visit, new COVID-19 diagnosis screening indicator during every visit, as well as any lab report indicating a positive test for SARS-CoV-2. Inconsistencies detected are referred to corporate nurses who directly communicate with individual clinic staff for resolution.

Exposure and Time at Risk

Each eligible patient who received treatment for at least one day during the study period contributed days-at-risk. Patients could move from being unvaccinated (defined by the CDC to include the period extending up to 13 days after the first vaccine dose)³ to partially vaccinated (for mRNA vaccines only; defined by the CDC as the period starting 14 days after the first mRNA vaccine dose up to 13 days after the 2^nd mRNA vaccine dose) to fully vaccinated (≥14 days after completing the manufacturer recommended final dose). Patients could contribute days-at-risk for each applicable category as long as they remained SARS-CoV-2 uninfected.

Case rates per 10,000 days at-risk and the composite outcome of COVID-related hospitalization or death for each vaccine status, and, in additional analyses among those fully vaccinated, for each vaccine type, were compared using a time dependent Cox proportional hazard models with unvaccinated patients as the reference group. The statistical model was subsequently adjusted for all baseline patient characteristics that differed at baseline among vaccination status within each time period (Table 1). Each patient’s state and county of residence was also used to adjust for geotemporal variability in the intensity of the epidemic and likelihood to follow mask wearing, social distancing and vaccine recommendations by incorporating daily county-level COVID-19 case rates and the percentage of Biden voters during 2020 US Presidential election, respectively.^11-13 Vaccine effectiveness and 95% CIs were calculated using the following: (1 – HR) x 100.¹⁴ We also determined case rates and vaccine effectiveness in a subset of patients vaccinated during the Delta variant dominant period.

Among patients with breakthrough COVID-19 diagnoses, we evaluated the subset with available anti-spike IgG titer results prior to the COVID-19 diagnosis. Results subsequently were de-identified and aggregated, and the association between the most proximate anti-spike IgG titer result and clinical outcomes was evaluated descriptively. Case rates per 10,000 days and adjusted hazard ratios for COVID-19 infection and composite for COVID-related hospitalization or death were calculated for anti-spike IgG values <1 (versus ≥1), < 2 (versus ≥2), <7 (versus ≥7) and <10 (versus ≥10). We selected the various cut-points to compare outcomes in those with undetectable levels of < 1 (reported by assay manufacturer) or < 2 (internal DCI laboratory validation), at assay threshold one index value above where COVID-related hospitalization or death not reported (anti-spike IgG value ≥7) and assay level recently reported as having higher odds for breakthrough infection (anti-spike IgG < 10).¹⁵

This study was reviewed and approved by the WCG IRB Work Order 1-1456342-1. Statistical analyses were performed using SAS v9.4.

Vaccination status and Vaccine Effectiveness against COVID-19 infection

There were 967 documented COVID-19 cases, with 511 (53%) occurring in unvaccinated patients and 579 (60%) occurring during the Delta dominant period. COVID-19 rates per 10,000 patient days and vaccine effectiveness for each time period between February 1 and October 2, 2021 are shown in Table 2. There were 362 (37%) cases that occurred among those considered fully vaccinated, with most of these breakthrough cases (n=335; 93%) occurring during the Delta dominant period; 92 (25%) of patients with breakthrough cases met CDC criteria for immunosuppressed. The median (IQR) time from being considered fully vaccinated to COVID-19 diagnosis was 133 (105 -156) days (Fig S1 Panel A). There was no difference in median days to breakthrough infection among vaccines: mRNA-1273/Moderna 137 (110, 158) days; BNT162b2/Pfizer 131 (102, 158) days; Ad26.COV2.S/Janssen 129 (100, 145) days; p=0.58 (Figure S1 Panel B).

Over the entire study period and compared to unvaccinated patients, the COVID-19 case rate was significantly lower in fully vaccinated than in unvaccinated patients: 2.0 vs 3.8 per 10,000 patient days [adjusted HR 0.15 (0.11, 0.20)](Table 2). Vaccine effectiveness was 85% overall, with mRNA-1273/Moderna vaccine having highest vaccine effectiveness at 88%followed by BNT162b2/Pfizer at 83% and Ad26.COV2.S/Janssen at 73%. COVID-19 case rates and vaccine effectiveness during the pre-Delta and Delta variant periods were markedly different. Among all vaccination status groups, COVID-19 case rates increased and vaccine effectiveness against infection decreased during the Delta period. Nonetheless, patients fully vaccinated had lower COVID-19 case rates (3.5 vs. 8.0 per 10,000 patient days [adjusted HR 0.22 (0.16, 0.30)]) and 78% vaccine effectiveness compared to unvaccinated patients during the Delta dominant period, with mRNA-1273/Moderna vaccine had highest vaccine effectiveness of 83%. In the subset analysis of patients vaccinated during the Delta variant dominant period, compared to unvaccinated patients, those fully vaccinated with mRNA-1273/Moderna experienced lowest case rate per 10,000 patient days and highest vaccine effectiveness against COVID-19 infection. (Table S1)

Vaccination status and Vaccine Effectiveness against COVID-19 related hospitalization or death

There were 361 COVID-19 related hospitalizations/deaths during the study period: 188 (52%) among unvaccinated, 41 (11%) among partially vaccinated, and 132 (37%) among fully vaccinated patients (Table 3). There were 24 COVID-19 related deaths (mRNA-1273/Moderna N=8; BNT162b2/Pfizer N=14; A26.COV2.S/Janssen N=2), with 19 (79%) occurring while hospitalized and 5 (21%) occurring while patient was at home. Nine (38%) patients having COVID-related death were considered immunocompromised. During the overall study period, the incidence of COVID-19 related hospitalization/death, was 1.35 per 10,000 patient days among unvaccinated and 0.43 per 10,000 patient-days among vaccinated patients [adjusted hazard ratio 0.19 (0.12, 0.30)]. For fully vaccinated patients the vaccine effectiveness was 81% overall (83% with mRNA-1273/Moderna, 75% with BNT162b2/Pfizer and 66% with A26.COV2.S/Janssen vaccine). (Table 3).

Among all vaccination status groups, both COVID-19 case rates and vaccine effectiveness against COVID-19 related hospitalization/death worsened during the Delta period. In the model comparing unvaccinated, partially vaccinated and fully vaccinated patients, fully vaccinated patients had lowest case rate per 10,000 patient days and adjusted HR for COVID-19 infection and related hospitalization/death in both pre-Delta and Delta dominant periods. In the model comparing unvaccinated, partially vaccinated and each vaccine, patients fully vaccinated with mRNA-1273/Moderna experienced lowest case rate per 10,000 patient days and highest vaccine effectiveness against COVID-19 related hospitalization/death in both pre-Delta and Delta variant dominant periods.

In the pre-Delta period, factors associated lower risk of COVID-19 related hospitalization or death included being vaccinated with BNT162b2/Pfizer (HR [95% CI]: 0.22 [0.07, 0.67]) and mRNA-1273/Moderna; (HR [95% CI]: 0.08 [0.02, 0.30]), whereas being female (HR [95% CI]: 1.55 [1.10, 2.20]) and residence in a congregate setting (HR [95% CI]: 2.21 [1.37, 3.28]) were associated with higher risk (Table S2). During the Delta variant dominant period, all vaccines were associated with lower risk of COVID-19 related hospitalization or death as well as higher serum albumin concentration and hepatitis B surface antibody ≥ 10 mIU/ml, signifying prior seroresponse to hepatitis B vaccine. Similar to the pre-Delta period, congregate living remained a significant risk factor for COVID-19 related hospitalization/death (HR [95% CI]: 1.97 [1.44, 2.70]) in the Delta dominant period. Diabetes as a comorbidity as well as increasing days since full vaccination status were associated with higher risk.

In the subset analysis of patients vaccinated during the Delta variant dominant period, compared to unvaccinated patients, those fully vaccinated experienced lowest case rate per 10,000 patient days and highest vaccine effectiveness against COVID-19 related hospitalization/death. (Table S1) Congregate living was the only factor associated with COVID-19 related hospitalization/death in patients vaccinated during the Delta variant dominant period. (Table S3)

Anti-spike IgG level and breakthrough COVID-19

Anti-spike IgG levels were available in 2,451 (22%) fully vaccinated patients over the study period. At each anti-spike IgG threshold evaluated, the lower anti-spike IgG level was associated with higher case rates per 10,000 days and adjusted hazard ratios for both infection (Table 4) and COVID-related hospitalization or death (Table 5).

There were 80 breakthrough infections (BNT162b2/Pfizer N=32, mRNA-1273/Moderna N=28, and Ad26.COV2.S/Janssen N=20) with the level most proximate to diagnosis measured a median (IQR) of 16 (8, 27) days prior to COVID-19 diagnosis. The frequency of COVID-19 cases requiring hospitalization across anti-spike IgG levels is shown in Figure 1. Half of breakthrough cases and the majority of COVID-related hospitalizations (20 of 29) occurred when the anti-spike IgG level was undetectable while an additional 4 hospitalizations and 12 total cases occurred at a level < 2, with the remaining hospitalizations occurring at antibody levels between 1 and 6. There were 8 patients with undetectable anti-spike IgG levels that experienced a COVID-19 related death following a hospitalization event (Figure 1).

• Download figure
• Open in new tab

Figure 1.

Patient anti-spike IgG value at time of COVID infection diagnosis (N=80)

*= COVID-related deaths (n=8); all occurring in patients having COVID-related hospitalization and in those having undetectable anti-spike IgG prior to infection.